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Abstract. Vascular endothelial growth inhibitor (VEGI) has been identified as an 
anti-angiogenic cytokine. However, the effects of VEGI174 protein, and its functional 
domain peptides V7 and V8, on renal cell carcinoma (RCC) remain unknown. In the 
present study, the protein and peptides were biosynthesised as experimental agents. 
The A498 and 786-O RCC cell lines, and an established mouse xenograft model, were 
separately treated with VEGI174, V7 or V8. Cellular functions, including 
proliferation, migration and invasion, were subsequently detected. Cell migration and 
invasion were monitored using the xCELLigence system. Furthermore, tumour 
growth and mouse behaviours, including mobility, appetite and body weight, were 
assessed. The results demonstrated that VEGI174, V7 and V8 inhibited the 
proliferation, migration and invasion of A498 and 786-O cell lines when administered 
at concentrations of 1 and 100 pM, 10 nM and 1 μM. The inhibitory effects exhibited 
dose- and time-dependent antitumour activity. Furthermore, VEGI174, V7 and V8 
inhibited tumour growth in A498 and 786-O xenograft mice. In the A498 xenografts, 
the tumour growth inhibition (TGI) rates in the VEGI174-, V7- and V8-treated groups 
were 71, 20 and 31%, respectively. In the 786-O xenografts, the TGI rates in the 
VEGI174-, V7- and V8-treated groups were 34, 26 and 31%, respectively. There was 
no significant loss in body weight and no cases of mortality were observed for all 
treated mice. In conclusion, VEGI174, V7 and V8 exhibited potential antitumour 
effects and were well tolerated in vivo. V7 and V8, as functional domain peptides of 




Renal cell carcinoma (RCC) is a common malignancy of the genitourinary system that 
accounts for 5% of new cancer cases in males and 3% in females worldwide; RCC 
was responsible for 14,240 cases of mortality in the United States of America in 2016 
(1). The majority of patients with localised RCC are effectively treated with radical 
nephrectomy, and 25-30% of these patients ultimately present with disseminated 
disease. Furthermore, nearly a third of patients who undergo surgery will experience 
recurrence or progression (2). The prognosis of metastatic RCC is poor, with a median 
overall survival of 12 months and a 5-year survival rate of <10% (3). 
 Over the past decade, steps have been made towards developing targeted 
therapies for patients with advanced RCC (4,5), which have increased the therapeutic 
response rate and improved survival outcomes. Tyrosine kinase inhibitors targeting 
vascular endothelial growth factor (VEGF) receptors are considered first-line 
therapies for RCC (6-8). In addition, RCC appears to be particularly sensitive to 
strategies that target tumour-associated angiogenesis; however, complete and 
long-term responses to the current targeted therapies are rare, and the cancer usually 
progresses (9). Notably, RCC is not a single disease but is a process associated with 
complex and heterogeneous tumourigenesis, which may confer resistance to targeted 
therapies (10,11). Therefore, it is essential that novel therapeutic strategies or targets 
be explored in future research. 
 Vascular endothelial growth inhibitor (VEGI) is a member of the tumour necrosis 
factor (TNF) superfamily, which has been identified as an anti-angiogenic cytokine 
(12,13). It is located on human chromosome 9q32 (Gene ID: 9966). The full-length 
VEGI gene is ~17 kb, and consists of four exons and three introns. Three alternatively 
spliced isoforms, VEGI174, VEGI192 and VEGI251, have been documented and 
share 151 common C-terminal amino acids (AAs) with different N-terminal regions. 
The initially reported VEGI protein consists of 174 AAs that can be divided into two 
parts: AA residues 1-25 at the N-terminus constitute an intracellular transmembrane 
domain, and AA residues 26-174 at the C-terminus form an extracellular domain 
(14,15). VEGI is highly expressed in kidney, bladder, prostate, lung, breast and colon 
tissues (16-21). Our previous studies revealed that overexpression of VEGI174 
significantly inhibited RCC cell proliferation, motility, adhesion and 
epithelial-mesenchymal transition (EMT) in vitro and in vivo (21-24). Taken together, 
these previous data suggested that VEGI174 exerts inhibitory effects on RCC; 
therefore, it may be valuable to be further study VEGI174 with regards to RCC 
treatment. 
 As an endothelial cell-secreted cytokine, the role of VEGI174 in RCC is unclear, 
and whether its functional domain peptides exert the same effects on RCC has yet to 
be reported. The present study designed different peptide fragments based on the 
functional domain of the VEGI174 protein. Furthermore, the biological functions of 
VEGI174 and its functional domain peptides were assessed on RCC in vitro and in 
vivo, and how well the compounds were tolerated was investigated. 
 
Materials and methods 
 
Selection of effective functional domains of VEGI174. The present study was 
approved by the ethics committee of Beijing Institute for Cancer Research (Beijing, 
China). Based on the human VEGI sequence (GenBank: NC_000009.12; 
https://www.ncbi.nlm.nih.gov/genbank/), eight different segments (V1-V8) were 
designed that encode the VEGI174 functional extracellular domains (23). In our 
prestudies, the full-length human VEGI174 and functional domain (V1-V8) genes 
were respectively cloned into mammalian expression plasmid vectors (pEF/His TOPO 
TA; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and were then 
transfected into human umbilical vein endothelial cells (HUVECs; American Type 
Culture Collection, Manassas, VA, USA). Briefly, HUVECs (confluence, 50-60%) 
were transfected with the vectors using Lipofectamine® 2000 (Invitrogen; Thermo 
Fisher Scientific, Inc.) at 37˚C for 10 h; overexpression was confirmed by western 
blotting and reverse transcription-quantitative polymerase chain reaction. An electric 
cell-substrate impedance sensing measuring system (ibidi GmbH, Planegg, Germany) 
revealed that overexpression of VEGI174 or V1-V8 was able to inhibit the motility 
and adhesion of HUVEC cells (25,26). Specifically, the inhibitory effects of 
overexpressing the V7 or V8 gene fragments were more significant (Fig. 1). Therefore, 
the full-length VEGI174 protein and V7 and V8 peptides were selected as target 
agents in the present study. 
 
Biosynthesis of the VEGI174 protein and its domain peptides. VEGI174 protein and 
its domain peptides (V7 and V8) were biosynthesised and qualified by the School of 
Pharmaceutical Sciences, Sun Yat-Sen University (Guangzhou, China). The AA 
sequence of the VEGI174 protein and its domain peptides are listed in Table I. 
 
Cell culture. The human RCC cell lines, A498 and 786-O, were provided by Sun 
Yat-Sen University Laboratory (Guangzhou, China). In vitro cell culture was 
conducted in Dulbecco’s modified Eagle medium (HyClone; GE Healthcare, Logan, 
UT, USA) or RPMI-1640 medium (HyClone; GE Healthcare), supplemented with 10% 
foetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and 100 U/ml 
penicillin and streptomycin (Gibco; Thermo Fisher Scientific, Inc.). Cells were grown 
at 37˚C in a humidified atmosphere containing 5% CO2-air. 
 
Animals. The animal studies were approved by the ethics committee of Beijing 
Institute for Cancer Research, and the Institutional Animal Care and Use Committee 
(IACUC) of Crown Bioscience (Beijing, China). Female BALB/c nude and 
NOD/SCID mice (n=5/group; age, 4-6 weeks; weight, 16-20 g; specific pathogen-free 
degree) were supplied by Beijing FuKang Bioscience (Beijing, China; Animal 
Certificate No. 11401300025891). Mice were maintained under the following 
conditions: Temperature, 18-22˚C; humidity, 50-60%; 12-h light/dark cycle; ad 
libitum food/water access Procedures related to animal handling, care and treatment in 
this study were performed according to the guidelines approved by the IACUC of 
Crown Bioscience and following the guidance of the Association for Assessment and 
Accreditation of Laboratory Animal Care. 
 
Cell proliferation assay. Cancer cells were harvested during the logarithmic growth 
phase and were counted using a Countstar automated cell counter (ALIT Life Science 
Co., Ltd., Shanghai, China). Cell concentration was adjusted to 5.0x104/ml in culture 
medium. Cell suspensions, ~100 µl/well, were seeded in 96-well plates (Corning 
Incorporated, Corning, NY, USA) and were cultured in a humidified incubator at 37˚C 
under 5% CO2 for 24 h. Subsequently, VEGI174 and its domain peptides (V7 and V8), 
at various concentrations, were separately added to each well at final concentrations 
of 1 and 100 pM, 10 nM and 1 μM. Cytoactivity was detected using a Cell Counting 
kit-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), according to 
the manufacturer’s protocol, at 24, 48, 72, 96 and 120 h. 
 Real-time measurement of cell migration and invasion. Cell migration and invasion 
were monitored using the xCELLigence system (Roche Applied Science, Penzberg, 
Germany) (27-29). To examine cell migration, the RCC cells were incubated in a cell 
invasion/migration (CIM)-plate 16 (8-μm pore size; Roche Applied Science) coated 
with fibronectin. The lower chambers were filled with fresh medium containing 10% 
FBS. The upper chambers were filled with serum-free medium, and the plate was 
incubated at 37˚C in an atmosphere containing 5% CO2. Subsequently, VEGI174 and 
its domain peptides (V7 and V8), at various concentrations, were separately added to 
each well, at final concentrations of 1 and 100 pM, 10 nM and 1 μM. The CIM-plate 
was assembled onto the Real-Time Cell Analyzer (RTCA) with dual-plate format 
instrument, and cell migration was assessed at 15-min intervals for 24-48 h. Data 
acquisition and analysis were performed using RTCA software (version 1.2; Roche 
Diagnostics, Basel, Switzerland). 
Invasion was measured with the RTCA in the same manner as migration; 
however, a layer of Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was added 
to the upper side of the membranes.  
 
In vivo xenograft studies. A498 and 786-O cell lines were implanted into NOD/SCID 
mice and BALB/c nude mice, respectively. Briefly, the mice were subcutaneously 
injected into the right flank with RCC cells (3x106) mixed with Matrigel (100 μl). 
Tumour dimensions were measured using a Vernier caliper. Tumour sizes were 
calculated using the following formula: Tumour volume (mm3) = (length x width2)/2. 
When the tumours grew to 130-190 mm3 in size, the animals were randomised into an 
untreated control group and treatment groups (n=5 mice/group). VEGI174, V7 and V8 
were administered as single agents, and PBS was used as a blank control. Mice were 
treated via intratumoural injections every other day and received a total of four doses 
(Q2Dx4; Table II). Tumour growth and behavioural data, including mobility, visual 
estimation of food and water consumption, and body weight alterations, were assessed 
twice weekly. 
 Effectiveness and safety assessment. Tumour growth inhibition (TGI) and tumour 
growth delay time (T-C) were calculated, in order to assess the response of the 
tumours to the agents. TGI was calculated using the following formula: TGI (%) = 
[(DVc-DVe)/DVc] x 100%, in which DVc is the difference between the final and 
initial tumour volumes of the blank control group, and DVe represents the change in 
tumour volume in each agent-treated group. T-C refers to the difference in time (days) 
required for a tumour to reach a certain volume between the implanted tumour of a 
treatment group and that of the control group; T is the number of days required for the 
treatment group to reach a specific tumour volume, and C represents the number of 
days required for the control group to reach the same value. 
 Mouse behaviour, including temperament, appetite, activity, body weight changes 
and cases of mortality were recorded, in order to conduct a safety evaluation. 
 
Statistical analysis. All statistical analyses were performed using SPSS software 
(version 20.0; IBM Corp., Armonk, NY, USA). The measured data (three replicates) 
are presented as the means ± standard deviation. One-way analysis of variance and a 
least-significant difference multiple comparisons test were used to analyse the 
equality of the means among three or more groups. P<0.05 was considered to indicate 




VEGI174, V7 and V8 inhibit the proliferation of RCC cells in vitro. Viability of A498 
and 786-O cells was continuously monitored for 5 days following treatment with the 
VEGI174 protein and the V7 and V8 peptides. Cell activity of the blank control group 
was set as the baseline. Compared with the blank control group, proliferation was 
inhibited following treatment with VEGI174, V7 and V8 at concentrations of 1 and 
100 pM, 10 nM and 1 μM in both cell lines (Fig. 2). The inhibitory effects of 
treatment on RCC cells exhibited a dose-dependent effect in vitro; however, the 
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inhibitory effects among the VEGI174-, V7- and V8-treated groups showed no 
significant differences (P>0.05). 
 
VEGI174, V7 and V8 inhibit RCC cell migration and invasion in vitro. The present 
study used the xCELLigence system to investigate whether the VEGI174 protein and 
V7 and V8 peptides were involved in the regulation of RCC cell migration and 
invasion. These assays revealed that VEGI174, V7 and V8 significantly inhibited the 
migration and invasion of A498 cells compared with the control group at 
concentrations of 10 nM and 1 μM (P<0.001; Fig. 3). Inhibition of cell migration and 
invasion exhibited dose- and time-dependent effects. As the treatment concentration 
increased, the inhibitory effect became more obvious. In addition, cell migration and 
invasion were more notably affected after ≥24 h of treatment. Conversely, no 
significant differences were observed in the inhibitory effects among the VEGI174-, 
V7- and V8-treated groups. 
Consistently, treatment with the VEGI174 protein and V7 and V8 peptides 
significantly inhibited the migration and invasion of 786-O cells compared with in the 
control group at concentrations of 10 nM and 1 μM (P<0.001; Fig. 4). Inhibition of 
cell migration and invasion exhibited dose- and time-dependent effects. Notably, cell 
migration and invasion were more obviously affected after ≥24 h of treatment. These 
findings suggested that the V7 and V8 peptides may inhibit RCC cell migration and 
invasion, as well as VEGI174 protein, in vitro. 
 
VEGI174, V7 and V8 suppress A498 xenograft growth in vivo. NOD/SCID mice were 
used to establish A498 xenografts. The effects of VEGI174, V7 and V8 were 
determined on A498 xenograft tumour growth over an 8-day (Q2Dx4) period (Fig. 5). 
Growth inhibition was observed in the VEGI174-, V7- and V8-treated groups 
compared with in the blank control group (Table III). The final tumour volume in the 
VEGI174-treated group was significantly smaller than that in the control group 
(P<0.05). The TGI of the VEGI174-treated group was 71%, which was higher than in 
the V7- (20%) and V8-treated (31%) groups. In A498 xenografts, for T-C analysis, the 
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average tumour volume was set at 350 mm3. The T-C values of the VEGI174-, V7- 
and V8-treated groups were 5, 1 and 3 days, respectively (Table III). There was no 
significant loss in body weight and no cases of mortality in all mice groups (Fig. 6A). 
The mice had a good temperament and appetite, and exhibited normal activity levels. 
Overall, VEGI174, V7 and V8 treatments were well tolerated and safe. 
 
VEGI174, V7 and V8 suppress 786-O xenograft growth in vivo. A second xenograft 
study was performed using 786-O cells to determine the effects of VEGI174, V7 and 
V8 on tumour growth over an 8-day (Q2Dx4) period (Fig. 7). TGI was also observed 
in the VEGI174-, V7- and V8-treated groups; however, the rates were not significant 
compared with in the blank control-treated group (Table IV). The TGI rates of the 
VEGI174-, V7- and V8-treated groups were 34, 26 and 31%, respectively. In 786-O 
xenografts, for T-C analysis, the average tumour volume was set at 300 mm3. The T-C 
values of the VEGI174-, V7- and V8-treated groups were 3.5, 1 and 1.5 days, 
respectively (Table IV). The body weights of all 786-O xenograft-implanted mice 
were stable, and there were no agent-related cases of mortality (Fig. 6B). The mice 
had a good temperament and appetite, and exhibited normal activity levels during the 
experimental period. These findings indicated that VEGI174, V7 and V8 were well 




VEGI174 is a cytokine that belongs to the TNF ligand family. It is abundantly 
expressed in endothelial cells and is a ligand for the TNF receptor superfamily 
member (TNFRSF)25 receptor and the TNFRSF21/death receptor 6 decoy receptor 
(30,31). Numerous studies have investigated its expression and biological functions in 
cancer, and have demonstrated that VEGI expression is absent in the tumour 
vasculature in various types of cancer (32,33). Parr et al (18) reported that VEGI is 
aberrantly expressed in breast cancer and has prognostic relevance. Patients with 
breast cancer with low expression levels of VEGI have a poorer prognosis than those 
with high VEGI expression. Our previous study also observed a decrease in the 
expression of VEGI in RCC tissues (22). In addition, Chew et al (14) demonstrated 
that overexpression of VEGI abrogates xenograft tumour progression by reducing 
tumour growth rate and microvessel density. It has also been demonstrated that 
overexpression of VEGI inhibits RCC cell motility, EMT, vascular endothelial tube 
formation and tumour growth (21-24). Furthermore, VEGI participates in regulating 
the biological functions of several tumour cell lines, including breast carcinoma 
(MCF-7), cervical carcinoma (HeLa) and myeloid tumour (U-937 and ML-1a) cell 
lines (34,35). 
Notably, Hou et al (36) reported that systemic administration of recombinant 
human VEGI192 protein gave rise to a marked inhibition of tumour growth and an 
increased survival time in a Lewis lung carcinoma murine tumour model. VEGI174 is 
one of three alternatively spliced isoforms of VEGI. It is important to further 
demonstrate how VEGI174 protein and its peptide fragments function in RCC. 
Among the VEGI174 functional domains, our prestudies verified that the inhibitory 
effects produced by the V7 and V8 domains are more significant than those produced 
by the other functional domains. In the present study, VEGI174 and its functional 
domain peptides (V7 and V8) were biosynthesized, and their effects on RCC 
proliferation, migration and invasion were detected. 
The cell viability of A498 and 786-O cell lines was inhibited following treatment 
with various concentrations of VEGI174, V7 and V8. In addition, the xCELLigence 
system clearly monitored A498 and 786-O cell migration and invasion. The data 
confirmed that VEGI174, V7 and V8 significantly regulated the cell migration and 
invasion of A498 and 786-O cells in vitro. Furthermore, inhibition of cell proliferation, 
migration and invasion exhibited dose- and time-dependent effects, which require 
further exploration. 
 The in vivo study provided support for the ability of VEGI174, V7 and V8 to 
inhibit RCC growth. TGI was observed in the A498 and 786-O xenograft models. In 
the A498 xenograft mice, the TGI rates of the VEGI174-, V7- and V8-treated groups 
were 71, 20 and 31%, respectively. The T-C values of the VEGI174-, V7- and 
V8-treated groups were 5, 1 and 3 days, respectively. In the 786-O xenografts, the 
TGI rates of the VEGI174-, V7- and V8-treated groups were 34, 26 and 31%, 
respectively. The T-C values of the VEGI174-, V7- and V8-treated groups were 3.5, 1 
and 1.5 days, respectively. These findings indicated that the V7 and V8 peptides were 
slightly inferior to the VEGI174 protein in terms of antitumour activity. The V7 and 
V8 peptides are only parts of the VEGI174 protein, and their spatial structures and 
biological functions are different; therefore, these features require more intensive 
study. Any drug resulting in a TGI of ≥58% (the National Cancer Institute standard 
criterion for antitumour activity) is considered a valid anticancer agent (37). VEGI174, 
V7 and V8 have exerted potential antitumour effects in vivo. Notably, the V7 and V8 
peptides inhibited RCC cell proliferation, migration and invasion as well as the 
VEGI174 protein did in vitro. These data strongly support the fact that V7 and V8 are 
important functional domains of VEGI174. 
 The safety and tolerance of the three agents were also evaluated in vivo. Mouse 
behaviour, including temperament, appetite, activity, body weight gain/loss and 
mortality, were recorded. The mice in all groups had no abnormal appearance or 
behaviour, all of the mice survived, and their body weights were stable. These results 
preliminarily demonstrated that VEGI174, V7 and V8 were safe and well tolerated. 
The VEGI174 protein and its domain peptides (V7 and V8) exhibited inhibitory 
effects on RCC proliferation, migration and invasion; however, the exact mechanism 
remains unclear. Zhang et al (38) reported that VEGF expression could be suppressed 
by VEGI-stimulated TNF superfamily member 15 activation of the Jun N-terminal 
kinase-GATA binding protein 3 signalling pathway. Qi et al (39) reported that VEGI 
inhibits vasculogenesis by regulating the relative levels of membrane-bound and 
soluble isoforms of VEGF receptor-1. Overall, these data suggested that the VEGI174 
protein and its domain peptides may negatively regulate the VEGF pathway, in order 
to inhibit tumour growth. Our previous study also demonstrated that there was an 
inverse correlation between VEGI174 and microvessel density (22). Notably, in the 
present study, it was demonstrated that the VEGI174 protein and V7 and V8 peptides 
inhibited the proliferation, migration and invasion of A498 and 786-O cells in vitro. 
These data indicated that VEGI174, and V7 and V8 peptides may directly interact 
with tumour cells and regulate cellular functions. In addition, the mechanism 
underlying the inhibitory effects of VEGI174 on tumour growth may not be limited to 
the VEGF pathway but may involve other signalling pathways; this should be 
analysed in future research. 
In conclusion, based on the overall antitumour activity of VEGI174, V7 and V8 
in RCC, V7 and V8 may be considered important functional domains of VEGI174. 
The differences in the secondary and tertiary structures between the V7 and V8 
peptides, and the VEGI174 protein, should be analysed in future studies, in order to 
improve antitumour effects and provide information for novel drug development. In 
addition, the regulatory mechanisms of VEGI174 and the V7 and V8 peptides on RCC 
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Figure 1. Cell adhesion and motility of HUVECs overexpressing full-length VEGI174, 
VEGI192 and VEGI251, and the VEGI174 functional fragments V1-V8, were 
detected using an electric cell-substrate impedance sensing cell function detector. (A 
and B) Overexpression of VEGI174, VEGI192, V4, V5, V7 and V8 inhibited HUVEC 
adhesion; V7 and V8 exhibited more potent inhibition than the other functional 
domain peptides. (C and D) Overexpression of VEGI174, VEGI192, V1, V4, V7 and 
V8 inhibited HUECV motility; V7 and V8 exhibited more potent inhibition than the 
other functional domain peptides. HUVECs, human umbilical vein endothelial cells; 
VEGI, vascular endothelial growth inhibitor.  
 
Figure 2. Effects of VEGI174 protein and V7 and V8 peptides on the proliferation of 
A498 and 786-O cells in vitro. Cell Cells were cultured in various concentrations of 
VEGI174, V7 and V8. proliferation was inhibited following treatment with VEGI174, 
V7 and V8 at concentrations of 1 and 100 pM, 10 nM and 1 μM in both cell lines (* 
P<0.05 vs. 1 pM). There was no significant difference in the inhibitory effects among 
the VEGI174-, V7- and V8-treated groups (P>0.05). Proliferation was assessed by 
Cell Counting kit-8. VEGI174, vascular endothelial growth inhibitor 174.  
 
Figure 3. Cell migration and invasion of A498 cells treated with VEGI174 protein and 
V7 and V8 peptides. Treatment significantly inhibited migration and invasion of A498 
cells VEGI174, V7 and V8 significantly inhibited the migration and invasion of A498 
cells at concentrations of 10 nM and 1 μM compared with in the control group (*** 
P<0.001 vs. the control group). VEGI174, vascular endothelial growth inhibitor 174. 
 
Figure 4. Cell migration and invasion of 786-O cells treated with VEGI174 protein 
and V7 and V8 peptides. VEGI174, V7 and V8 significantly inhibited the migration 
and invasion of A498 cells at concentrations of 10 nM and 1 μM (*** P<0.001 vs. the 
control group)Treatment significantly inhibited the migration and invasion of 786-O 
cells compared with in the control group (P<0.001). VEGI174, vascular endothelial 
growth inhibitor 174. 
 
Figure 5. Tumour volume alterations in A498 xenografts. Once the implanted tumours 
grew to ~190 mm3 in size, mice were randomised into the blank control group and 
treatment groups (n=5 mice/group). VEGI174, V7 and V8 were administered as single 
agents, and PBS was added as a blank control via intratumoural injection every other 
day for a total of four doses. (A) Blank control group; (B) VEGI174-treated group; 
(C): V7-treated group; and (D) V8-treated group mice. (E) The final tumour volume 
of the VEGI174-treated group was significantly smaller than that of the control group 
(* P<0.05 vs. the control group). VEGI174, vascular endothelial growth inhibitor 174. 
 
Figure 6. (A) Body weight alterations in the A498 xenograft mice. At the end of 
the study, the average weight of the blank control group was 21.7±2.1 g, and the 
average weights for the VEGI174-, V7- and V8-treated groups were 23.9±0.9, 
23.3±0.6 and 23.9±0.7 g, respectively (P>0.05). (B) Body weight alterations in the 
786-O xenograft mice. At the end of the study, the average weight of the blank control 
group was 23.2±0.7 g, and the average weights for the VEGI174-, V7- and V8-treated 
groups were 20.3±0.4, 22.6±0.6 and 22.2±0.7 g, respectively (P>0.05). VEGI174, 
vascular endothelial growth inhibitor 174. 
 
Figure 7. Tumour volume alterations in the 786-O xenograft mice. Once the implanted 
tumours had grown to ~130 mm3 in size, mice were randomised into the blank control 
group and treatment groups (n=5 mice/group). VEGI174, V7 and V8 were 
administered as single agents, and PBS was used as a blank control via intratumoural 
injection every other day for a total of four doses. (A) Blank control group; 
(B)VEGI174-treated group; (C) V7-treated group; and (D) V8-treated group mice. (E) 
The final tumour volume of the VEGI174-, V7- and V8-treated groups was smaller 
than that of the control group; however, this was  not statistically significant 
(P>0.05). VEGI 174, vascular endothelial growth inhibitor 174. 
 
Tables 
Table I. Amino acid sequence of VEGI174 protein (V7 peptide contains AA 81-145, 
V8 peptide contains AA 118-145). 
Name AA sequence 
Commented [EE5]: Please use symbols to indicate the 
significance between specific groups in the graph. 
 
For example, if there is a significant difference between the 
Blank control and VEGI174 groups at 12 days place a symbol 
(e.g.*) above the 1 Blank control data point and define this in 
the figure legend, e.g. *P<0.05 vs. VEGI174 group. 
Commented [BH6R5]: As you suggested, we have used 
symbols to indicate significance between specific groups in 
Figure 5. Please check it. Thank you. 
VEGI174a 
MRRFLSKVYS FPMRKLILFL VFPVVRQTPT QHFKNQFPAL 
HWEHELGLAF/50 AA 
TKNRMNYTNK FLLIPESGDY FIYSQVTFRG MTSECSEIRQ 
AGRPNKPDSI/100 AA 
TVVITKVTDS YPEPTQLLMG TKSVCEVGSN WFQPIYLGAM 
FSLQEGDKLM/150 AA 
VNVSDISLVD YTKEDKTFFG AFLL/174 AA  
aGenBank accession number: AAD08783.1. AA, amino acid; VEGI174, vascular 
endothelial growth inhibitor 174. 
 




Route Administration time 
















aPBS was used as a blank control. VEGI, vascular endothelial growth inhibitor. 
 
Table III. TV, TGI and T-C following treatment with VEGI174, V7 and V8 in A498 
xenografts. 
Group T-C (days) 
TV before 
treatment (mm3) 
TV after final 
treatment (mm3) 




187±28 838±50 — — 
VEGI174 5 192±9 383±30 71 0.006 
V7 1 196±12 672±43 20 0.685 
V8 3 196±14 595±50 31 0.501 
aCompared with TV after final treatment in the blank control group. T-C, tumour 
growth delay time; TGI, tumour growth inhibition; TV, tumour volume. 
 
Table IV. TV, TGI and T-C following treatment with VEGI174, V7 and V8 in 786-O 
xenografts. 
Group T-C (days) 
TV before 
treatment (mm3) 
TV after final 
treatment (mm3) 




129±22 447±30 — — 
VEGI174 3.5 130±13 341±35 34 0.171 
V7 1 129±17 364±45 26 0.547 
V8 1.5 127±17 345±40 31 0.427 
aCompared with the TV after final treatment in the blank control groupT-C, tumour 
growth delay time; TGI, tumour growth inhibition; TV, tumour volume. 
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